Elite in Spinal Muscular Atrophy (SMA)

Janbernd Kirschner

Freiburg, BW, DE 
Elite in Spinal Muscular Atrophy (SMA)
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Janbernd Kirschner practices in Freiburg, Germany. Kirschner is rated as an Elite expert by MediFind in the treatment of Spinal Muscular Atrophy (SMA). Their top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Duchenne Muscular Dystrophy, and Becker Muscular Dystrophy.

Their clinical research consists of co-authoring 197 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 66 articles and participated in 1 clinical trial in the study of Spinal Muscular Atrophy (SMA).

Locations

Freiburg, BW, Germany
Other Locations
Essen, NW 45147, Germany
Bonn, NW, Germany
Halle, NI 06120, Germany
Freiberg, SN, Germany
Hannover, NI, Germany
Stuttgart, BW 70184, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Enrollment Status: Active_not_recruiting
Publish Date: March 14, 2025
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
View 5 Less Clinical Trials

197 Total Publications

Phenotypic intrafamilial variability of 5q-associated spinal muscular atrophy: A systematic multicentre sibling study.
Phenotypic intrafamilial variability of 5q-associated spinal muscular atrophy: A systematic multicentre sibling study.
Journal: Journal of neuromuscular diseases
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kirschner's expertise for a condition
ConditionClose
View All 42 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile